Login
search
Contact Us

Gray Matters from Epilepsia

Gray Matters

2016 Gray Matters

August

  • Commentary and responses:
    • Vigabatrin efficacy in GPR56-associated polymicrogyria: The role of GABAA receptor pathway
    • Commentary and response: Clinical significance of CYP2C9-status-guided valproic acid therapy in children
  • Announcements

July

  • Letters and responses:
    • Comment on the recent ILAE special report on the definition and classification of status epilepticus
  • Announcements

June

  • Letters and responses:
    • Rasmussen encephalitis tissue transfer program
    • No evidence of thalamic metabolic abnormality associated with continuous spike-and-wave during sleep
    • Elite athletes and epilepsy
    • Towards a quantitative assessment of psychogenic nonepileptic seizures
  • Announcements

May

  • Letters and responses:
    • Psychogenic nonepileptic seizures and sex differences in stress responses
    • Eslicarbazepine-induced toxic epidermal necrolysis
    • Brain atrophy in seizure-free temporal lobe epilepsy: Implications for predicting pharmacoresistance
  • Announcements

April

  • Letters and responses:
    • Availability of antiepileptic drugs: Politicians’ roles
    • Postencephalitic epilepsy in children and adults: Etiology matters
    • Comment on outcome following multiple subpial transection in Landau-Kleffner syndrome and related regression
  • Announcements

March

  • Letters:
    • Is there a difference between various presentations of valproate for cognitive outcome after in utero exposure?
    • Clobazam-induced pedal edema: “An unrecognized side effect of a common antiepileptic drug”
  • Announcements

 

Home | Contact Us | Privacy & Security | Login | Sitemap
Creative Commons License
Text on this website is available under a
Creative Commons Attribution-ShareAlike 4.0 International License
except all videos and images, which remain copyrighted by the International League Against Epilepsy.